Supplementary Figure 1

1
Supplementary Figure b a USP2a -actin No transf. Lipo Vector pUSP2a WT 48 h 72 h LNCaP No transf. Lipo Vector pUSP2a WT Vector (1) pUSP2a WT (2) % Apoptosis (sub-G 1 ) Contr CDDP DXT Doxo 1 2 1 2 1 2 1 2 Contr CDDP DXT Doxo cPARP -actin LNCaP 3 4 3 4 3 4 3 4 Contr CDDP DXT Doxo siContr (3) siUSP2a (4) Contr CDDP DXT Doxo LNCaP cPARP -actin % Apoptosis (sub-G 1 ) d c USP2a -actin 48 h 72 h No transf. Lipo siContr siUSP2a No transf. Lipo siContr siUSP2a LNCaP Supplementary Figure 1 USP2a triggers chemo-resistance in LNCaP prostate cancer cells. (a, c) Evaluation of USP2a protein expression, and (b, d) apoptosis analysis by sub-G 1 and PARP cleavage (cPARP) carried out in drug- treated LNCaP cells undergoing transient transfection, as follows: without DNA or silencing oligos (Lipo), with pCDNA3 (Vector, 1), pCDNA3_USP2a WT (2), with siControl oligos, (3) or specific siUSP2a oligos (4). (e) Evaluation of drug response in the indicated LNCaP clones carried out by clonogenic assay. 39 e Survival (%) CDDP (µg/ml) DTX (nM) Doxo (µM) USP2a MUT USP2a WT EV LNCaP USP2a MUT USP2a WT EV LNCaP USP2a MUT USP2a WT EV LNCaP

TAGS:

description

Supplementary Figure 1. siContr (3). Vector (1). pUSP2a WT (2). siUSP2a (4). USP2a. USP2a. - actin. - actin. DXT. DXT. Doxo. Doxo. Contr. CDDP. Contr. CDDP. a. c. LNCaP. b. d. LNCaP. LNCaP.  EV.  EV.  EV.  USP2a MUT.  USP2a MUT.  USP2a MUT. - PowerPoint PPT Presentation

Transcript of Supplementary Figure 1

Page 1: Supplementary Figure 1

Supplementary Figure 1

b

a

USP2a

-actin

No

tran

sf.

Lipo

Vec

tor

pUS

P2a

WT

48 h 72 h LNCaP

No

tran

sf.

Lipo

Vec

tor

pUS

P2a

WT

Vector (1) pUSP2aWT (2)

% A

popt

osis

(su

b-G

1)

Contr CDDP DXT Doxo

1 2 1 2 1 2 1 2Contr CDDP DXT Doxo

cPARP

-actin

LNCaP

3 4 3 4 3 4 3 4Contr CDDP DXT Doxo

siContr (3)siUSP2a (4)

Contr CDDP DXT Doxo

LNCaP

cPARP

-actin%

Apo

ptos

is (

sub-

G1)

d

c

USP2a

-actin

48 h 72 h

No

tran

sf.

Lipo

siC

ontr

siU

SP

2a

No

tran

sf.

Lipo

siC

ontr

siU

SP

2a

LNCaP

Supplementary Figure 1 USP2a triggers chemo-resistance in LNCaP prostate cancer cells.

(a, c) Evaluation of USP2a protein expression, and (b, d) apoptosis analysis by sub-G1 and PARP cleavage (cPARP) carried out in drug-treated LNCaP cells undergoing transient transfection, as follows: without DNA or silencing oligos (Lipo), with pCDNA3 (Vector, 1), pCDNA3_USP2aWT (2), with siControl oligos, (3) or specific siUSP2a oligos (4). (e) Evaluation of drug response in the indicated LNCaP clones carried out by clonogenic assay.39

e

Sur

viva

l (%

)

CDDP (µg/ml) DTX (nM) Doxo (µM)

USP2aMUT

USP2aWT

EV

LNCaP

USP2aMUT

USP2aWT

EV

LNCaP

USP2aMUT

USP2aWT

EV

LNCaP

Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Supplementary Figure 1 - Welcome to the UCLA …€¦ ·  · 2016-06-151 Supplementary Figure 1 Supplementary Figure 1. ... Supplementary Figure 5 Supplementary Figure 5. ... JP10089

Supplementary Figure 1.

Supplementary Figure 1.

Supplementary Figures: Supplementary Figure 1 – PANCAN ...df6sxcketz7bb.cloudfront.net/manuscripts/88000/88755/jci.insight.88755.sd.pdfSupplementary Figures: Supplementary Figure

Supplementary Figures: Supplementary Figure 1 – PANCAN ...df6sxcketz7bb.cloudfront.net/manuscripts/88000/88755/jci.insight.88755.sd.pdfSupplementary Figures: Supplementary Figure

Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Supplementary Figure 1 - Nature · Supplementary Figure 1 ... Supplementary Figure 3. Activation of HIF-1 activity by UCHL1 overexpression. ... EMT6/EF-Luc/EV-1, 2 and

Supplementary Figure 1: Dependence of hysteresis in IV ...10.1038/s41467-017... · Supplementary Figure 1 . Supplementary Figure 1: Dependence of hysteresis in IV measurements upon

Supplementary Figure 1: Dependence of hysteresis in IV ...10.1038/s41467-017... · Supplementary Figure 1 . Supplementary Figure 1: Dependence of hysteresis in IV measurements upon

LEGENDS TO SUPPLEMENTARY FIGURES Supplementary Figure 1 ...

LEGENDS TO SUPPLEMENTARY FIGURES Supplementary Figure 1 ...

media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

media.nature.com · 1 Supplementary Materials Supplementary Table S1 Supplementary Table S2 Supplementary Table S3 Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure

Supplementary figure 1

Supplementary figure 1

Supplementary Figure Legends Supplementary Fig. 1: Genetic ...10.1038... · 1 Supplementary Figure Legends Supplementary Fig. 1: Genetic engineering of the immunoglobulin HC locus

Supplementary Figure Legends Supplementary Fig. 1: Genetic ...10.1038... · 1 Supplementary Figure Legends Supplementary Fig. 1: Genetic engineering of the immunoglobulin HC locus

Ahmed Supplementary Figure 1

Ahmed Supplementary Figure 1

Supplementary figure 1

Supplementary figure 1

Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B.

Supplementary Figure 1. Supplementary Figure 2 Supplementary Figure 3 A B.

Supplementary Figure 1

Supplementary Figure 1

Supplementary Figure 1

Supplementary Figure 1

images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

images.nature.com · Web viewSupplementary Figure 7 Supplementary Figure 3 Supplementary Figure 1 Supplementary Materials Supplementary Figures S1-S7 Supplementary Tables S1-S7 Clinical

Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary

Supplementary information for: Discovery and … · Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary